Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
- Details
- Category: AstraZeneca
AstraZeneca and MSD Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7 to 5 to recommend Lynparza (olaparib) as a 1st-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer), whose disease has not progressed following 1st-line platinum-based chemotherapy.
Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement.
Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed
- Details
- Category: AstraZeneca
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm).
New set-up for IT at Bayer
- Details
- Category: Bayer
Bayer is transforming its IT function to further accelerate the digitalization of the company. Leading IT providers will take over standardized services, such as the provision of digital workplaces for employees or the global operation of IT infrastructure. Internally, the IT function will focus on differentiating solutions for Bayer's businesses.
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
- Details
- Category: AstraZeneca
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody drug conjugate (ADC) and potential new medicine, in patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens.
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
- Details
- Category: Novartis
Novartis holded an investor event in London to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D pipeline.
Vas Narasimhan, CEO of Novartis, said “Novartis had a year of breakthrough innovation in 2019, with five potential blockbuster NME approvals. The near term brings yet another catalyst-rich period with pipeline progress across the portfolio that can sustain long-term growth.
Roche and Spark Therapeutics, Inc. announce extension of tender offer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without
More Pharma News ...
- AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
- AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
- FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions
- Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
- Bayer selects Pharmaron as partner organization
- FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy
- Amgen completes acquisition of Otezla® (apremilast)